309 related articles for article (PubMed ID: 24047340)
21. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
[TBL] [Abstract][Full Text] [Related]
22. Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study.
Schneider U; Sumila M; Robotka J; Weber D; Gruber G
Radiat Oncol; 2014 Feb; 9():58. PubMed ID: 24548307
[TBL] [Abstract][Full Text] [Related]
23. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
[TBL] [Abstract][Full Text] [Related]
24. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
[TBL] [Abstract][Full Text] [Related]
25. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy.
Edvardsson A; Kügele M; Alkner S; Enmark M; Nilsson J; Kristensen I; Kjellén E; Engelholm S; Ceberg S
Acta Oncol; 2019 Jan; 58(1):95-104. PubMed ID: 30280626
[TBL] [Abstract][Full Text] [Related]
26. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
Ntentas G; Dedeckova K; Andrlik M; Aznar MC; George B; Kubeš J; Darby SC; Cutter DJ
Pract Radiat Oncol; 2019 May; 9(3):179-187. PubMed ID: 30708133
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
[TBL] [Abstract][Full Text] [Related]
28. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.
Stokkevåg CH; Indelicato DJ; Herfarth K; Magelssen H; Evensen ME; Ugland M; Nordberg T; Nystad TA; Hægeland C; Alsaker MD; Ulven K; Dale JE; Engeseth GM; Boer CG; Toussaint L; Kornerup JS; Pettersen HES; Brydøy M; Brandal P; Muren LP
Acta Oncol; 2019 Oct; 58(10):1416-1422. PubMed ID: 31364899
[No Abstract] [Full Text] [Related]
29. Volumetric-modulated arc therapy (VMAT) versus 3D-conformal radiation therapy in supra-diaphragmatic Hodgkin's Lymphoma with mediastinal involvement: A dosimetric comparison.
Higby C; Khafaga Y; Al-Shabanah M; Mousa A; Ilyas M; Nazer G; Khalil EM
J Egypt Natl Canc Inst; 2016 Sep; 28(3):163-8. PubMed ID: 27245145
[TBL] [Abstract][Full Text] [Related]
30. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
31. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
Seco J; Gu G; Marcelos T; Kooy H; Willers H
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
[TBL] [Abstract][Full Text] [Related]
32. Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?
De Sanctis V; Bolzan C; D'Arienzo M; Bracci S; Fanelli A; Cox MC; Valeriani M; Osti MF; Minniti G; Chiacchiararelli L; Enrici RM
Radiat Oncol; 2012 Aug; 7():129. PubMed ID: 22857015
[TBL] [Abstract][Full Text] [Related]
33. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.
Sachsman S; Hoppe BS; Mendenhall NP; Holtzman A; Li Z; Slayton W; Joyce M; Sandler E; Flampouri S
Leuk Lymphoma; 2015 Jul; 56(7):2019-24. PubMed ID: 25315071
[TBL] [Abstract][Full Text] [Related]
34. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.
Toltz A; Shin N; Mitrou E; Laude C; Freeman CR; Seuntjens J; Parker W; Roberge D
J Appl Clin Med Phys; 2015 Sep; 16(5):167–178. PubMed ID: 26699298
[TBL] [Abstract][Full Text] [Related]
35. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.
Horn S; Fournier-Bidoz N; Pernin V; Peurien D; Vaillant M; Dendale R; Fourquet A; Kirova YM
Cancer Radiother; 2016 Apr; 20(2):98-103. PubMed ID: 26992750
[TBL] [Abstract][Full Text] [Related]
36. Does VMAT for treatment of NSCLC patients increase the risk of pneumonitis compared to IMRT ? - a planning study.
Bertelsen A; Hansen O; Brink C
Acta Oncol; 2012 Jul; 51(6):752-8. PubMed ID: 22248064
[TBL] [Abstract][Full Text] [Related]
37. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
38. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
[TBL] [Abstract][Full Text] [Related]
39. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
40. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
Girinsky T; Pichenot C; Beaudre A; Ghalibafian M; Lefkopoulos D
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):218-26. PubMed ID: 16169675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
